|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...5051525354555657585960...6768» |
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial initiation date: Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (clinicaltrials.gov) - Jan 24, 2013
P2, N=14, Recruiting, Sponsor: New York University School of Medicine
Initiation date: Aug 2012 --> Jan 2013
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment open: Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (clinicaltrials.gov) - Jan 24, 2013
P2, N=14, Recruiting, Sponsor: New York University School of Medicine
Initiation date: Aug 2012 --> Jan 2013 Suspended --> Recruiting
- ||||||| Kovaltry (octocog alfa) / Bayer, CSL Behring
Trial completion, Head-to-Head: Leopold II: A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A (clinicaltrials.gov) - Jan 24, 2013
P3, N=80, Completed, Sponsor: Bayer
Suspended --> Recruiting Active, not recruiting --> Completed
- | Benlysta (belimumab) / GSK
Enrollment change: A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. (clinicaltrials.gov) - Jan 23, 2013
P2, N=48, Not yet recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=30 --> 48
- | carfilzomib / Generic mfg.
Clinical: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib (clinicaltrials.gov) - Jan 23, 2013
P2, N=36, Recruiting, Sponsor: Ajai Chari
- Recomodulin (recombinant thrombomodulin alfa) / Asahi Kasei
Trial withdrawal: Study to Look at the Effects of ART-123 on Patients With Sepsis and Disseminated Intravascular Coagulation (DIC) (clinicaltrials.gov) - Jan 22, 2013
P2b, N=0, Withdrawn, Sponsor: University of South Alabama
N=30 --> 48 Completed --> Withdrawn
- Proleukin (aldesleukin) / Novartis, Prometheus, Iovance Biotherap
Enrollment change: Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients (clinicaltrials.gov) - Jan 22, 2013
P1/2, N=10, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Completed --> Withdrawn N=15 --> 10
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Enrollment change: Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients (clinicaltrials.gov) - Jan 22, 2013
P1/2, N=13, Completed, Sponsor: SCRI Development Innovations, LLC
N=15 --> 10 N=50 --> 13
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Bortezomib-Dexamethasone-Doxorubicin-Study (clinicaltrials.gov) - Jan 22, 2013
P2, N=72, Completed, Sponsor: Austrian Forum Against Cancer
N=50 --> 13 N=40 --> 72
- Proleukin (aldesleukin) / Novartis, Prometheus, Iovance Biotherap
Trial completion: Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients (clinicaltrials.gov) - Jan 22, 2013
P1/2, N=10, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=40 --> 72 Recruiting --> Completed
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Trial completion: Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients (clinicaltrials.gov) - Jan 22, 2013
P1/2, N=13, Completed, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Completed Active, not recruiting --> Completed
- nelarabine / Generic mfg.
Trial termination: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma (clinicaltrials.gov) - Jan 21, 2013
P2, N=111, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Administratively complete.
- | bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment closed: IFM/DFCI2009: Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (clinicaltrials.gov) - Jan 21, 2013
P3, N=700, Active, not recruiting, Sponsor: University Hospital, Toulouse
Completed --> Terminated; Administratively complete. Recruiting --> Active, not recruiting
- | Enrollment closed, HEOR: IMAJEM: Imaging Young Myeloma (IMAgerie JEune My (clinicaltrials.gov) - Jan 17, 2013
P3, N=155, Active, not recruiting, Sponsor: Nantes University Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- bortezomib / Generic mfg.
Trial completion, Metastases: Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia (clinicaltrials.gov) - Jan 16, 2013
P2a, N=34, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- peripheral blood stem cell transplantation / National Cancer Institute
Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Jan 15, 2013
P=N/A, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- Yervoy (ipilimumab) / Ono Pharma, BMS
New P1/2 trial, Combination therapy: Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) - Jan 14, 2013
P1/2, N=69, Suspended, Sponsor: Stanford University
- | RG7444 / Roche
Trial completion: A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma (clinicaltrials.gov) - Jan 14, 2013
P1, N=14, Completed, Sponsor: Genentech
Not yet recruiting --> Completed Active, not recruiting --> Completed
- ispinesib (SB-715992) / Cytokinetics
Trial termination, Metastases: SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 10, 2013
P1, N=31, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Administratively Complete.
- Enrollment change, Surgery: Goal-orientated Therapy of Perioperative Disturbance in Hemostasis in Cardiac Surgery (clinicaltrials.gov) - Jan 9, 2013
P4, N=200, Completed, Sponsor: University Hospital, Basel, Switzerland
Completed --> Terminated; Administratively Complete. N=90 --> 200
- vincristine / Generic mfg.
Enrollment change: Bryostatin and Vincristine in B-Cell Malignancies (clinicaltrials.gov) - Jan 9, 2013
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
N=90 --> 200 N=25 --> 18
- Trial completion, Surgery: Goal-orientated Therapy of Perioperative Disturbance in Hemostasis in Cardiac Surgery (clinicaltrials.gov) - Jan 9, 2013
P4, N=200, Completed, Sponsor: University Hospital, Basel, Switzerland
N=25 --> 18 Recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial withdrawal: S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jan 8, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Recruiting --> Completed Completed --> Withdrawn
- R-(-)-gossypol (AT 101) / Ascentage Pharma
Enrollment change, Combination therapy, Surgery, Metastases: Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 8, 2013
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Withdrawn N=24 --> 36
- Rituxan (rituximab) / Roche
Enrollment change: S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jan 8, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
N=24 --> 36 N=50 --> 0
- | roneparstat (LB401) / Leadiant Biosci
New P1 trial, Metastases: SST0001 (Roneparstat) in Advanced Multiple Myeloma (clinicaltrials.gov) - Jan 8, 2013
P1, N=30, Recruiting, Sponsor: Sigma Tau Research Switzerland SA
- R-(-)-gossypol (AT 101) / Ascentage Pharma
Trial completion, Combination therapy, Surgery, Metastases: Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 8, 2013
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 0 Terminated --> Completed
- Signifor LAR (pasireotide long acting release) / Recordati
Trial withdrawal, Combination therapy: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus (clinicaltrials.gov) - Jan 7, 2013
P2, N=0, Withdrawn, Sponsor: Milton S. Hershey Medical Center
Terminated --> Completed Not yet recruiting --> Withdrawn
- Signifor LAR (pasireotide long acting release) / Recordati
Enrollment change, Combination therapy: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus (clinicaltrials.gov) - Jan 7, 2013
P2, N=0, Withdrawn, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Withdrawn N=40 --> 0
- | Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial completion: Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222 (clinicaltrials.gov) - Jan 7, 2013
P1, N=18, Completed, Sponsor: Bayer
N=40 --> 0 Recruiting --> Completed
- Campath (alemtuzumab) / Sanofi
Trial withdrawal: Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Jan 6, 2013
P2, N=0, Withdrawn, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Completed Completed --> Withdrawn
- Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial termination: Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Jan 6, 2013
P1, N=0, Terminated, Sponsor: Jonsson Comprehensive Cancer Center
Completed --> Withdrawn Completed --> Terminated; no accrual
- | indatuximab ravtansine (BT-062) / Grifols
Trial completion: Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 6, 2013
P1, N=32, Completed, Sponsor: Biotest Pharmaceuticals Corporation
Completed --> Terminated; no accrual Active, not recruiting --> Completed
- |||| bortezomib / Generic mfg., dexamethasone / Generic mfg.
Trial completion: Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse (clinicaltrials.gov) - Jan 6, 2013
P2, N=101, Completed, Sponsor: Peter MacCallum Cancer Centre, Australia
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research (clinicaltrials.gov) - Jan 3, 2013
P=N/A, N=75, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | NovoThirteen (catridecacog) / Novo Nordisk
Enrollment closed: mento 2: Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (clinicaltrials.gov) - Jan 3, 2013
P3, N=60, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- sorafenib / Generic mfg.
Enrollment change: Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 3, 2013
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=23 --> 40
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment closed: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jan 3, 2013
P1, N=42, Active, not recruiting, Sponsor: Mayo Clinic
N=23 --> 40 Recruiting --> Active, not recruiting
- Promacta (eltrombopag) / Novartis
Enrollment open: Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT (clinicaltrials.gov) - Jan 2, 2013
P=N/A, N=16, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Suspended --> Recruiting
- Trial withdrawal: S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jan 1, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Suspended --> Recruiting Active, not recruiting --> Withdrawn
- Enrollment change: S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jan 1, 2013
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Active, not recruiting --> Withdrawn N=90 --> 0
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, IO biomarker: Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (clinicaltrials.gov) - Dec 20, 2012
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
N=90 --> 0 Suspended --> Completed
- imatinib / Generic mfg.
Trial completion: Imatinib Mesylate in Treating Patients With Myelofibrosis (clinicaltrials.gov) - Dec 20, 2012
P2, N=18, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Active, not recruiting --> Completed
- ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial termination: Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia (clinicaltrials.gov) - Dec 19, 2012
P2, N=10, Terminated, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Completed --> Terminated; Schering-Plough discontinued supplying study drug.
- New P4 trial: Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Dec 19, 2012
P4, N=0, Withdrawn, Sponsor: St. Olavs Hospital
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial termination: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 19, 2012
P2, N=62, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Schering-Plough discontinued supplying study drug. Active, not recruiting --> Terminated
- ||||| dexamethasone / Generic mfg., bendamustine / Generic mfg., pomalidomide / Generic mfg.
Clinical: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (clinicaltrials.gov) - Dec 19, 2012
P1/2, N=56, Recruiting, Sponsor: Cristina Gasparetto
- NovoSeven (eptacog alfa) / Novo Nordisk
Enrollment closed, Observational data: Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B (clinicaltrials.gov) - Dec 18, 2012
P=N/A, N=40, Active, not recruiting, Sponsor: Novo Nordisk
Active, not recruiting --> Terminated Enrolling by invitation --> Active, not recruiting
- ||| bortezomib / Generic mfg.
Trial initiation date: Velcade Consolidation Bone Study (clinicaltrials.gov) - Dec 18, 2012
P2, N=106, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Enrolling by invitation --> Active, not recruiting Initiation date: Jun 2009 --> Sep 2009
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Enrollment closed: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Dec 18, 2012
P2, N=50, Active, not recruiting, Sponsor: University of Nebraska
Initiation date: Jun 2009 --> Sep 2009 Recruiting --> Active, not recruiting